toremifene (Q3993743)

toremifene (English)

19 October 2016

C₂₆H₂₈ClNO

1 reference

toremifene (English)

19 November 2016

CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3

1 reference

toremifene (English)

19 November 2016

CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3

1 reference

https://www.whocc.no/atc_ddd_index/?code=L02BA02

toremifene (English)

19 November 2016

60 milligram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

World Health Organisation international non-proprietary name

toremifene (English)

1 reference

toremifene (English)

medical condition treated

19 October 2016

1 reference

significant drug interaction

13 December 2016

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

vandetanib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

chlorpromazine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

1 reference

A reference set of clinically relevant adverse drug-drug interactions

anagrelide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

moxifloxacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

dronedarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

crizotinib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pimozide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

zuclopenthixol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

pasireotide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

mefloquine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

fingolimod

1 reference

A reference set of clinically relevant adverse drug-drug interactions

domperidone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ondansetron

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ivabradine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amiodarone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ondansetron

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-methadone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

disopyramide

1 reference

A reference set of clinically relevant adverse drug-drug interactions

erythromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

droperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

haloperidol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sotalol

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ivabradine

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-sulpiride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

clarithromycin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

route of administration

oral administration

0 references

LiverTox likelihood score

LiverTox toxicity likelihood category D

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Toremifene

last update

6 June 2016

subject has role

selective estrogen-receptor modulators

2 references

5 March 2018

Medical Subject Headings

MeSH descriptor ID

D017312

bone density conservation agents

15 March 2018

1 reference

Medical Subject Headings

MeSH descriptor ID

D017312

hormonal antineoplastic agent

15 March 2018

1 reference

InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-

Medical Subject Headings

15 March 2018

Toremifene

0 references

Identifiers

InChI

1 reference

toremifene (English)

19 November 2016

2 references

toremifene (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

89778-26-7

2 references

toremifene (English)

19 November 2016

https://commonchemistry.cas.org/detail?cas_rn=89778-26-7

9 April 2021

1 reference

Toremifene (English)

19 November 2016

1 reference

toremifene (English)

19 November 2016

mapping relation type

2 references

TOREMIFENE (English)

19 November 2016

International Chemical Identifier

InChI

InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-

1 reference

TOREMIFENE (English)

19 November 2016

2 references

inferred from InChIKey

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

1 reference

2 references

DSSTOX compound identifier

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.125.139

27 December 2018

ECHA Substance Infocard ID

Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl- (English)

quotation

CAS no.: 89778-26-7 (English)

100.125.139

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.125.139

27 December 2018

Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl- (English)

quotation

CAS no.: 89778-26-7 (English)

1 reference

Guide to Pharmacology Ligand ID

Toremifene (English)

publication date

17 November 2015

4325

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

4325

D02.455.426.559.389.150.700.900.900

toremifene (English)

19 November 2016

Toremifene

0 references

MeSH concept ID

M0026287

0 references

MeSH tree code

0 references

RxNorm ID

38409

1 reference

toremifene (English)

19 November 2016

1 reference

Human Metabolome Database ID

HMDB0014679

2 references

based on heuristic

inferred from InChIKey

2 references

toremifene (English)

19 November 2016

MedlinePlus drug identifier

0 references

1 reference

toremifene (English)

19 November 2016

0 references

1 reference

1 reference

toremifene (English)

19 October 2016

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

toremifene (English)

19 October 2016

0 references

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

1 reference

5JQ7 (English)

19 October 2016

1 reference

toremifene (English)

19 November 2016

0 references

toremifeeni

toremifen

toremifene

1 reference

YSO-Wikidata mapping project